Fischer SK - Search Results

1

Characterization of robust immune responses to a bispecific antibody, a novel class of antibody therapeutics.

Peng K, Siradze K, Fischer SK. Peng K, et al. Among authors: fischer sk. Bioanalysis. 2021 Feb;13(4):239-252. doi: 10.4155/bio-2020-0281. Epub 2021 Feb 12. Bioanalysis. 2021. PMID: 33576267

2

Clinical immunogenicity specificity assessments: a platform evaluation.

Peng K, Siradze K, Quarmby V, Fischer SK. Peng K, et al. Among authors: fischer sk. J Pharm Biomed Anal. 2011 Feb 20;54(3):629-35. doi: 10.1016/j.jpba.2010.09.035. Epub 2010 Oct 29. J Pharm Biomed Anal. 2011. PMID: 21035975

3

Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.

Araujo J, Zocher M, Wallace K, Peng K, Fischer SK. Araujo J, et al. Among authors: fischer sk. J Pharm Biomed Anal. 2011 Jul 15;55(5):1041-9. doi: 10.1016/j.jpba.2011.03.008. Epub 2011 Mar 11. J Pharm Biomed Anal. 2011. PMID: 21466939

4

Utilizing design of experiments to characterize assay robustness.

Cowan KJ, Erickson R, Sue B, Delarosa R, Gunter B, Coleman DA, Gilbert H, Song A, Fischer SK. Cowan KJ, et al. Among authors: fischer sk. Bioanalysis. 2012 Sep;4(17):2127-39. doi: 10.4155/bio.12.199. Bioanalysis. 2012. PMID: 23013395

5

Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy.

Baker DL, Peng K, Cheu M, Fischer SK. Baker DL, et al. Among authors: fischer sk. Curr Med Res Opin. 2014 May;30(5):913-22. doi: 10.1185/03007995.2013.877435. Epub 2014 Jan 24. Curr Med Res Opin. 2014. PMID: 24354863 Clinical Trial.

6

When assay format matters: a case study on the evaluation of three assay formats to support a clinical pharmacokinetic study.

Peng K, Baker D, Brignoli S, Cabuhat J, Fischer SK. Peng K, et al. Among authors: fischer sk. AAPS J. 2014 Jul;16(4):625-33. doi: 10.1208/s12248-014-9594-7. Epub 2014 Apr 22. AAPS J. 2014. PMID: 24752719 Free PMC article.

7

Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22.

Baker DL, Peng K, Cheu M, Fischer SK. Baker DL, et al. Among authors: fischer sk. Curr Med Res Opin. 2014 Oct;30(10):1927-9. doi: 10.1185/03007995.2014.938150. Epub 2014 Jul 7. Curr Med Res Opin. 2014. PMID: 24960148 No abstract available.

8

Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study.

Peng K, Xu K, Liu L, Hendricks R, Delarosa R, Erickson R, Budha N, Leabman M, Song A, Kaur S, Fischer SK. Peng K, et al. Among authors: fischer sk. MAbs. 2014;6(6):1500-8. doi: 10.4161/mabs.36208. MAbs. 2014. PMID: 25484037 Free PMC article. Clinical Trial.

9

Strategies to compare clinical antitherapeutic antibody data when changing assay platforms: a case study.

Qiu ZJ, Ying Y, Lewin-Koh SC, Coleman D, Brignoli S, Hendricks R, Siguenza P, Quarmby V, Fischer SK, Song A. Qiu ZJ, et al. Among authors: fischer sk. Bioanalysis. 2015;7(14):1775-83. doi: 10.4155/bio.15.91. Bioanalysis. 2015. PMID: 26270784

10

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.

Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG. Hanania NA, et al. Among authors: fischer sk. Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5. Lancet Respir Med. 2016. PMID: 27616196 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters